Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 6, 2014, Pages 995-1003

  Østvik, Ann E ^a,b   Granlund, Atle Vb ^a   Gustafsson, Bjørn I ^a,b   Torp, Sverre H ^a,b   Espevik, Terje ^a   Mollnes, Tom E ^a,c,d,e   Damås, Jan K ^a,b   Sandvik, Arne K ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORDLAND HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Complement factor B; Inflammatory bowel disease; Intestinal epithelium; TLR3

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; C REACTIVE PROTEIN; COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; INTERFERON INDUCING AGENT; POLYINOSINIC POLYCYTIDYLIC ACID; TLR3 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; CELL CULTURE; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; ENDOSCOPIC BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYNTHESIS; ADULT; AGED; BIOPSY; CLINICAL TRIAL (TOPIC); COMPLEMENT ALTERNATIVE PATHWAY; CROHN DISEASE; DRUG EFFECTS; FEMALE; GENE SILENCING; GENETICS; HT 29 CELL LINE; IMMUNOLOGY; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; ULCERATIVE COLITIS; YOUNG ADULT;

ADULT; AGED; BIOPSY; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; CROHN DISEASE; FEMALE; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; INTERFERON INDUCERS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; POLY I-C; TOLL-LIKE RECEPTOR 3; TRANSCRIPTOME; YOUNG ADULT;

EID: 84902165493     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000035     Document Type: Article

References (36)

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011; 474: 298-306.
2. Ricklin D, Lambris JD Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013; 190: 3831-3838.
3. Barilla-Labarca M.L., Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013; 148: 313-321.
4. Okroj M, Heinegard D, Holmdahl R., et al Rheumatoid arthritis and the complement system. Ann Med. 2007; 39: 517-530. (Pubitemid 350035568)
5. Sanders ME, Koski CL, Robbins D, et al Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol. 1986; 136: 4456-4459. (Pubitemid 16090661)
6. Ostvik AE, Granlund AV, Bugge M, et al Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Tolllike receptor 3 stimulation. Inflamm Bowel Dis. 2013; 19: 265-274.
7. Ostvik AE, Granlund AV, Torp S.H., et al Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol. 2013; 173: 502-511.
8. Brentano F, Schorr O, Gay R.E., et al RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005; 52: 2656-2665. (Pubitemid 41369093)
9. Kariko K, Ni H, Capodici J., et al mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279: 12542-12550. (Pubitemid 38445825)
10. Harboe M, Ulvund G, Vien L., et al The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004; 138: 439-446. (Pubitemid 39573623)
11. Matsumoto M, Fukuda W, Circolo A., et al Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A. 1997; 94: 8720-8725. (Pubitemid 27335106)
12. Harboe M, Garred P, Karlstrom E., et al The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol. 2009; 47: 373-380.
13. Halstensen TS, Mollnes TE, Fausa O, et al Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut. 1989; 30: 361-366. (Pubitemid 19091163)
14. Halstensen TS, Mollnes TE, Garred P, et al Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology. 1990; 98: 1264-1271. (Pubitemid 20143112)
15. Halstensen TS, Mollnes TE, Garred P, et al Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut. 1992; 33: 902-908.
16. Zimmermann-Nielsen E., Gronbaek H, Dahlerup J.F., et al Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. BMC Gastroenterol. 2005; 5: 31.
17. Potter BJ, Brown DJ, Watson A, et al Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease. Gut. 1980; 21: 1030-1034. (Pubitemid 11184246)
18. Hodgson HJ, Potter BJ, Jewell DP Humoral immune system in inflammatory bowel disease: I. Complement levels. Gut. 1977; 18: 749-753. (Pubitemid 8196473)
19. Granlund A, Flatberg A, Ostvik A.E., et al Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One. 2013; 8:e56818.
20. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25: 402-408. (Pubitemid 34164012)
21. Bergseth G, Ludviksen JK, Kirschfink M, et al An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013; 56: 232-239.
22. Gentleman RC, Carey VJ, Bates D.M., et al Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5:R80.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3.
24. Zhou Y, Guo M, Wang X., et al TLR3 activation efficiency by high or low molecular mass poly I:C. Innate Immun. 2013; 19: 184-192.
25. Chin AC, Parkos CA Neutrophil transepithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. Ann N Y Acad Sci. 2006; 1072: 276-287. (Pubitemid 44448460)
26. Sordal O, Qvigstad G, Nordrum I.S., et al In situ hybridization in human and rodent tissue by the use of a new and simplified method. Appl Immunohistochem Mol Morphol. 2013; 21: 185-189.
27. Cole FS, Matthews WJ Jr, Marino JT, et al Control of complement synthesis and secretion in bronchoalveolar and peritoneal macrophages. J Immunol. 1980; 125: 1120-1124. (Pubitemid 10048948)
28. Zou L, Feng Y, Li Y., et al Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol. 2013; 191: 5625-5635.
29. Ahrenstedt O, Knutson L, Nilsson B., et al Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med. 1990; 322: 1345-1349. (Pubitemid 20154477)
30. Andoh A, Fujiyama Y, Bamba T., et al Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J Immunol. 1993; 151: 4239-4247. (Pubitemid 23298757)
31. Andoh A, Fujiyama Y, Sakumoto H., et al Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas. Clin Exp Immunol. 1998; 111: 477-483. (Pubitemid 28160888)
32. Schepp-Berglind J., Atkinson C, Elvington M., et al Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012; 188: 6309-6318.
33. Jain U, Woodruff TM, Stadnyk AW The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol. 2013; 168: 488-501.
34. Chen G, Yang Y, Gao X., et al Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest. 2011; 91: 472-483.
35. Woodruff TM, Arumugam TV, Shiels I.A., et al A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003; 171: 5514-5520. (Pubitemid 37432841)
36. Barratt-Due A., Thorgersen EB, Egge K, et al Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombo-genicity, and hemodynamic changes in porcine sepsis. J Immunol. 2013; 191: 819-827.